These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29240500)

  • 21. Dichotomous location of 160 atypical femoral fractures.
    Koeppen VA; Schilcher J; Aspenberg P
    Acta Orthop; 2013 Dec; 84(6):561-4. PubMed ID: 24286566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The advantages of tomosynthesis for evaluating bisphosphonate-related atypical femur fractures compared to radiography.
    Petraszko A; Siegal D; Flynn M; Rao SD; Peterson E; van Holsbeeck M
    Skeletal Radiol; 2016 May; 45(5):615-23. PubMed ID: 26861160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical femur fractures: a complication of prolonged bisphosphonate therapy?
    Girgis CM; Seibel MJ
    Med J Aust; 2010 Aug; 193(4):196-8. PubMed ID: 20712536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Femoral Fractures Following Long-term Bisphosphonate Use.
    Sheibani-Rad S
    Orthopedics; 2016 Nov; 39(6):e1036-e1040. PubMed ID: 27536951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Scapular Spine Fracture Defined on the Basis of a Bisphosphonate: a Case Report and Review of the Literature.
    Ilyas G; Senyuva G
    Acta Chir Orthop Traumatol Cech; 2022; 89(4):312-314. PubMed ID: 36055673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate-associated atypical femur fracture in a 90-year-old Caucasian woman.
    Gopinath KG; Shibu PK
    Hong Kong Med J; 2015 Jun; 21(3):286.e2-3. PubMed ID: 26045077
    [No Abstract]   [Full Text] [Related]  

  • 27. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
    Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cumulative effect of bisphosphonates and statins on stress fractures. Is it a failure of steroid biosynthesis? Case Report.
    Dzugan SS; Dzugan SA
    Neuro Endocrinol Lett; 2016; 37(2):97-101. PubMed ID: 27179570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical femoral fractures associated with long-term bisphosphonate use.
    Chatterjee S
    CMAJ; 2013 Oct; 185(14):1248. PubMed ID: 23649415
    [No Abstract]   [Full Text] [Related]  

  • 30. Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report.
    Puah KL; Tan MH
    Acta Orthop; 2011 Jun; 82(3):380-2. PubMed ID: 21561306
    [No Abstract]   [Full Text] [Related]  

  • 31. The other side tells the story.
    Mathur N; Lau KK
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):69-70. PubMed ID: 32043320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical femoral fractures: a complication of prolonged bisphosphonate therapy?
    Falkenberg MP
    Med J Aust; 2011 Jan; 194(2):102-3; author reply 103. PubMed ID: 21241227
    [No Abstract]   [Full Text] [Related]  

  • 33. Epidemiology, radiology and histology of atypical femoral fractures.
    Schilcher J
    Acta Orthop Suppl; 2013 Dec; 84(352):1-26. PubMed ID: 24303865
    [No Abstract]   [Full Text] [Related]  

  • 34. Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series.
    Bögl HP; Aspenberg P; Schilcher J
    Osteoporos Int; 2017 Aug; 28(8):2439-2444. PubMed ID: 28474166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
    Aspenberg P; Schilcher J; Fahlgren A
    Acta Orthop; 2010 Aug; 81(4):460-2. PubMed ID: 20515438
    [No Abstract]   [Full Text] [Related]  

  • 36. [Atypical femoral fracture in patient with over 12 years of unsupervised bisphosphonate therapy].
    Ramos-Pascua LR; Mencía-Barrio R; Casas-Ramos P; Sánchez-Lázaro J
    Rev Esp Geriatr Gerontol; 2015; 50(1):46-7. PubMed ID: 25443784
    [No Abstract]   [Full Text] [Related]  

  • 37. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.
    Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
    Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical forearm fractures associated with long-term use of bisphosphonate.
    Moon J; Bither N; Lee T
    Arch Orthop Trauma Surg; 2013 Jul; 133(7):889-92. PubMed ID: 23619919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biphosphonate-induced femoral stress fractures : A new problem and knowledge so far - case report].
    Lenz R; Ellenrieder M; Skripitz R; Bader R; Pautke C; Mittelmeier W; Tischer T
    Orthopade; 2011 Dec; 40(12):1111-8. PubMed ID: 21678088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study.
    Vasikaran SD
    Osteoporos Int; 2009 Aug; 20(8):1457-8. PubMed ID: 19436933
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.